ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health Care • China
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bearish•Quantitative Analysis
•06 Mar 2020 16:58

Shorts on Hong Kong Banks Continue Rising

We take a look at the latest SFC data released today evening on short position reporting in Hong Kong for the week ended 28 February 2020.Total...

Logo
443 Views
Share
bullish•Wuxi Biologics
•13 Feb 2020 09:51

Company Spotlight: Buy WuXi Biologics Inc. (2269-HK)

Health Care remains one of our favorite Sector overweights, both globally (ex-US) and in Greater China. We believe WuXi Biologics offers a timely...

Logo
410 Views
Share
bullish•Quantitative Analysis
•10 Feb 2020 16:31

HK Connect Flows: $1.3bn Inflows in Three Days After CNY

In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...

Logo
379 Views
Share
bullish•Quantitative Analysis
•06 Feb 2020 17:56

HK Connect Flows: What Chinese Buy/Sell on the First Day After Chinese New Year?

In this note, we would take a quick look at the top buys and sells by Chinese investors on the first day of trading over the Hong Kong Connect...

Logo
477 Views
Share
•29 Jan 2020 07:51

EM Pullback Opportunity

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point,...

Logo
544 Views
Share
x